Yvonne Efebera, MD 6-Jun-17

CURRICULUM VITAE

NAME: Yvonne Adeduni Efebera, MD, MPH Addrress: 320 W 10th Ave

A346 Starling Loving Hall Columbus, OH 43210

Office Phone 614-293-2268 Fax 614-366-5970 E-Mail Yvonne.efebera@osumc.edu EDUCATION 8/2012-12/2014 Masters of Public Health, The Ohio State University 7/2008-7/2009 Clinical and Research Fellowship, Stem Cell and Marrow Transplantation,

University of Texas, MD Anderson Cancer Center 1515 Holcombe Blvd, FC5.3017, Houston TX 77030 6/2004-6/2008 Fellowship, Hematology/Oncology Boston University Medical Center 750 Albany Street, Boston, MA 02118 6/2004-6/2008 Hematology Research Training Grant NHLBI Sponsored Mentor- Dr. David Sherr, Department of Environmental Health

Boston University Medical Center, 715 Albany Street, Boston, MA 02118 7/1998-6/2001 Residency, Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio. 8/1994-5/1998 Medical School, Pennsylvania State University, College of Medicine, Hershey,

Pennsylvania. Degree: Doctorate of Medicine (M.D) 9/1990-5/1994 Undergraduate, University of the District of Columbia, Washington, D.C. Major:

Chemistry. Degree: Bachelor of Science (B.Sc), Summa Cum Lauda. LICENSURE AND CERTIFICATION 2002 ABIM Internal Medicine 2008 ABIM Medical Oncology 2000 State of Ohio License (#35.078732) (UPIN H48926) (NPI 1285612986) 2004 State of Massachusetts Medical Board 2008 State of Texas Medical Board ACADEMIC APPOINTMENTS 06/2015-present Ohio State University Associate Professor Department of Internal Medicine

Division of Hematology 8/2009-6/2015 Ohio State University Assistant Professor Department of Internal Medicine

Division of Hematology

Yvonne Efebera, MD 6-Jun-17

7/2008-7/2009 Clinical and Research Fellowship, Stem Cell and Marrow Transplantation,

University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, FC5.3017, Houston TX 77030

8/2007-12/2007 Chief Fellow Hematology/Oncology Fellowship Program

Boston University Medical Center 10/2004–6/2008 Quincy Medical Center Moonlighter

114 Whitwell St, Quincy, MA 02169 10/2001-6/2004 Ohio Permanente Medical Group Staff Physician Department of Internal Medicine. Office: 19999 Rockside Road, Bedford, OH 44146

Privileges: Cleveland Clinic Foundation, Marymount Hospital, Summa Health Systems, Parma Community Hospital

SPECIALTY:

Internal Medicine, Hematology/Oncology, Blood and Marrow Stem Cell Transplantation. AWARDS AND HONORS 2017 Excellence in Teaching Award, Department of Internal Medicine. OSU 2017 Candidate for the President and Provost’s Leadership Institute- in Process 2017 Mid-Career Minority Leadership Seminar- selected to attend June 15-17, 2017 2014 Recognized as Top 10 percent of providers Nationally for patient satisfaction 2012 Featured in “Journey to Innovation”, portraying the work that international Faculty

members are doing 2011-pres West Virginia WVCTSI Ohio State CCTS Partnership Pilot Award 2010-pres Recognition for teaching medical students and Participating in CAPS 2009-pres K12 Institutional award, The Ohio State University, Comprehensive Cancer

Center 2007 Recipient of the VA Boston Healthcare System Golden Heart Award for

Outstanding Service 1990-1994 Dean’s List, University of the District of Columbia 1991-1994 Member, Beta Kappa Chi National Scientific Honor Society 1991-1994 Participant of the Honors Undergraduate Research Training Program with the

National Institute of Health-Minority Access to Research Careers (NIH-MARC). 1994 The American Chemical Society Award for best graduating senior

in Chemistry. University of the District of Columbia 1991 The William Curtis Award for Outstanding Junior in Chemistry. PROFESSIONAL MEMBERSHIPS: American Society of Hematology American Society of Clinical Oncology American Society for Blood and Marrow Transplantation Massachusetts Medical Society American College of Physicians. American Medical Association Society for General Internal Medicine American Society of Internal Medicine

Yvonne Efebera, MD 6-Jun-17

INTERNATIONAL/NATIONAL/INSTITUTIONAL PROFESSIONAL ORGANIZATIONS/COMMITTEES International 2012-present International Amyloidosis Adjudication Committee for Millennium-Takeda C16011

Amyloidosis study. 2013-present Adjudication Committee for actute GVHD on the Michigan State acute GVHD

International Consortium (MAGIC) study 2012-Present Adjudication committee for BMT.CTN-0702: A Trial of Single Autologous Transplant With

or Without Consolidation Therapy Versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma

2014-Present On expert panel for the combined Blood and Marrow Transplant Clinical Trials Network

Myeloma Intergroup Committee and the International Myeloma Foundation 2014-Present Member Blood and Marrow Transplant/ Clinical Trials Network(BMT/CTN) Committee 2014-present Editorial board member, Journal of Hematology and Thrombosis 2014-present Protocol member and writing committee member BMT/CTN 1302 2015-present Co-chair A061304: Phase Ib study of Ibrutinib +lenalidomide in relapse multiple myeloma

patients 2015-Present Speaker’s Bureau, Takeda Pharmaceutical 2016 Karyopharm Adjudication Committee 2017- Faculty advisor for educational materials development for Multiple Myeloma Disease

Awareness Program- Sponsored by Janssen 2017- Independent Adjudication review Committee Millenium-Takeda C16019, C16014 Multiple

Myeloma studies 2017- Editorial Board, Annals of Medical Case Reports: Hematology Case Reports 2017- Speaker’s Bureau, Janssen Pharmaceutical 2017- Multiple Myeloma Steering Committee- Janssen- in process National 2015- Speaker’s Bureau and Committee Member: Cultural Perspectives in Oncology: Multiple

Myeloma and African American Patients: Understanding a Complex Disease and Issue: Takeda Pharmaceutical

2012-present OSU representative to The Alliance, Myeloma Transplant Committee 2012-present BMT/CTN Committee for Transplant and Myeloma 2012-present Adjudication Committee for the BMT/CTN 0702 Study Institutional 2015-present Medical school admission committee member 2015-present Learning Communities Small Group Leader for Medical Students 2013 Member, Search for Division Director of Palliative Care, The Ohio State University 2013-present Member, BMT GVHD Grading Committee Chair, OSU Comprehensive Cancer Center 2013-present Member BMT Translational Research Committee, OSU Comprehensive Cancer Center 2010 Member, Medical Staff Advisory Committee, OSU Comprehensive Cancer Center 2010-pres Member, Ethics Committee, OSU Comprehensive Cancer Center 2009-pres Member, Multiple Myeloma Opportunities for Research and Education (MMORE), OSU

Comprehensive Cancer Center 2005-2008 Member, Board of Trustees, Preferred Home Health Care. Randolph, MA

Yvonne Efebera, MD 6-Jun-17

2004-2008 Member, Committee of Interns and Residents (CIR), Boston University Medical Center 2002-2004 Member, Advisory Board, Kaiser Permanente 2002-2004 Member, Bioethics Committee and Diversity Board, Kaiser Permanente 1998 Member, Residency Recruitment Drive for Internal Medicine, Howard University 1996-1998 Member, Student National Medical Association (SNMA) National Conferences 1995-1996 Vice President, Amnesty International, Pennsylvania State University 1995-1996 Vice President and Treasurer of the Student National Medical 1995 Mentor and Preceptor of the first year entering Medical Students. 1993-1994 President and Secretary of the Beta Kappa Chi National Honor Society - University of the

District of Columbia 1993-1994 Mentor - high school students, Beth Israel Deaconess Hospital, Boston, Massachusetts Editorial Service Reviewer: BLOOD Journal Bone Marrow Transplant Cancer Journal Clinical Advances in Hematology and Oncology Biology of Blood and Marrow Transplantation British Journal of Haematology Leukemia and Lymphoma Annals of Medicine PLOS ONE Expert Opinion on Investigational drugs Invited Commentary: BLOOD Journal Clinical Advances in Hematology and Oncology Grant Review 2013-present Grant Reviewer for Multiple Myeloma Opportunities for Research and Education Invited Commentary 2011 Invited Commentary: Necrobiotic Xanthogranuloma. Clin Adv Hematol Oncol.. 2014 Invited Commentary: C1013G/CXCR4 acts as a driver mutation of tumor progression and

modulator of drug resistance in lymphoplasmacytic lymphoma. BLOOD Journal. 2015 Invited commentary: “Should stem cell transplantation remain a preferred first-line

treatment option for patients with multiple myeloma?”. HemOnc Today. 2016 Invited Commentary/Article: Multiple Myeloma in African Americans: Columbus African

American News Journal INVITED BOOK CHAPTER REVIEWS: 2010 ASCO Educational Book Manuscript 2010: Hematopoietic Stem Cell Transplantation for

Acute Myelogenous Leukemia: Who Should Be Transplanted in First Complete Remission? Educational Book - Category: Leukemia, Myelodysplasia, and Transplantation

2014 Williams Hematology, 9th Edition: Classification and clinical manifestations of lymphocyte

and plasma cell disorders.

Yvonne Efebera, MD 6-Jun-17

Clinical Service 2009-present Attending Physician. Hematology 1 (Lymphoma & Myeloma) 2009-present Attending Physician. Bone Marrow Transplant Service 2009-present Attending Physician. Outpatient Myeloma Clinic Teaching Didactic 2014-present Lecturer – “Amyloidosis”, College of Medicine, Medical Student Lecture Series, The Ohio State University 2014-present Lecturer-“Patient Interview/Discussion”, College of Medicine, Medical Student Lecture Series, The Ohio State University 2013-present Lecturer- —“Multiple Myeloma”. Radiation/Oncology Residency Program 2012-present Tutor in Math and Science, Local High School Students, Columbus, Ohio 2009-present Lecturer – “Multiple Myeloma and Related Diseases”, Internal Medicine Residency

Lecture Series, The Ohio State University 2009-present Lecturer – “Amyloid Review”, Hematology/Oncology Fellowship Lecture Series, The Ohio

State University 2009-present Lecturer—“Multiple Myeloma” Hematology/Oncology Fellowship Board Review, The Ohio State University 2010-present Lecturer – “Blood and Marrow Transplantation”, Internal Medicine Residency Lecture

Series, The Ohio State University. Clinical Teaching 2015 – Pres Leader: Med1-4 Learning Communities 2013 – pres. Preceptorship – Lead.Serve.Inspire (LSI) Curriculum, Clinical Foundations I, Longitudinal Practice, The Ohio State University 2010 –pres Preceptorship – Clinical Assessment and Problem Solving (CAPS) Longitudinal

Preceptorship, The Ohio State University 2010 – pres Preceptorship – Med 1 Doctor Patient Relationship Preceptorship, The Ohio State

University 2010 – pres Preceptorship – Med 2 Hospital Based Preceptorship, The Ohio State University 2010 – pres Preceptorship – Med 3 and 4 Clerkship (Ambulatory and In-Patient). Internal

Medicine/Hematology, The Ohio State University ACADEMIC ADVISING AND MENTORSHIP TO STUDENTS, FELLOWS, AND JUNIOR FACULTY International Fellows and Trainees 2016 ASCO IDEA Grant Co-Mentor with Dr. Richard Goldberg. Visiting scholar is Narmin

Talibova, National Oncology Center, Baku Azerbaijan. 2017 ASCO IDEA Grant Co-Mentor with Dr. Gregg Otterson Visiting scholar is Maria Diana

Aileen Chua Bautista, University of Santo Tomas Hospital Philippines Mentoring of Physicians 2016-pres Parvathi Raganathan, Ph.D: Division of Hematology, Ohio State University 2017 Amro Stino, MD, Division of Neurology, Ohio State University Mentoring of Medicine Residents and Fellows 2010-2012 Neil Dunivan, Graduate Resident-Clinical Research, ASH Abstract and ASH Travel

Award, The Ohio State University

Yvonne Efebera, MD 6-Jun-17

2011 Joyce Habib, Graduate Resident-Clinical Research, ASH Abstract, The Ohio State University

2012-2013 Galena Salem, Graduate Resident-Fellowship Research, Internal Medicine, The Ohio State University

2013 Benjamin Chu, Graduate Resident-Fellowship Research, Internal Medicine, The Ohio State University

2015-Pres Sara Singer, Graduate Resident- clinical research, EHA Abstract, The Ohio State

University 2016-Pres Bin Ni, Graduate Resident- clinical research, The Ohio State University Mentoring of Undergraduate Students 2011 Selamawit Admasu, Undergraduate, College of Medicine, The Ohio State University Mentoring of Medical Students 2012-present Akshata Pandit, Med 2, Internal Medicine, The Ohio State University Mentoring of Student Groups 2011 MD Camp for Undergraduates, The Ohio State University 2016 MD Camp for Undergraduates, The Ohio State University PEER-REVIEW PUBLICATIONS

1. Ni B, Rosko A, Benson DM, Devine S, Hofmeister CC, Efebera YA. Efficacy of Autologous Stem

Cell Transplantation for the Treatment of Multiple Myeloma in HIV-positive patients-A case Series. Manuscript in Process

2. Stino AM, Efebera YE. Lenalidomide-responsive anti-MAG Neuropathy. Manuscript in review Muscle and Nerve.

3. Pandit QA, Wei L, Bustamante L, Elder P, Falk W, Sell M, Devine H, Rosko AE, Benson DM, Devine SM, Hofmeister CC, Efebera YA,. Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT). Manuscript submitted

4. Yvonne A. Efebera, Amy S. Ruppert, Apollinaire Ngankeu, Sabrina Garman, Prasanthi Kumchala, Steven M. Devine, Parvathi Ranganathan and Ramiro Garzon. Serum MicroRNA-155 level in Acute Graft-Versus-Host-Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT). Manuscript submitted

5. Hassan Issa, MD; Amy S. Ruppert M.A.S, Patrick Elder, M.S; Craig C.Hofmeister,MD.MPH; Don M. Benson, MD.Ph.D; Sam Penza, MD; Leslie Andritsos, MD; Rebecca Klisovic,MD; Sumithira Vasu, MBBS; William Blum, MD; Basem William, MBBS; Samantha Jaglowski, MD. MPH; Steven M. Devine, MD; Yvonne A. Efebera, MD.MPH. Comparison of Two Doses of Antithymocyte Globulin in Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Manuscript in process

6. Sara Singer, MD*; Yvonne A. Efebera, MD, MPH*; Qiuhong Zhao, MS; Donna Abounader, MS; Patrick Elder, MS; Craig C.Hofmeister, MD, MPH; Don M. Benson, MD, Ph.D; Sam Penza, MD; Leslie Andritsos, MD; Rebecca Klisovic, MD; Sumithira Vasu, MBBS; William Blum, MD2; Samantha Jaglowski, MD, MPH2; Basem M. William, MD2; Brian Bolwell, MD; Brad Pohlman, MD; Matt Kalaycio, MD; Deepa Jagadeesh, MD, MPH; Brian Hill, MD, Ph.D; Ronald Sobecks, MD; Navneet Majhail, MD, MS; Steven M. Devine, MD; Robert Dean, MD. A Two-Center Comparison of BEAM vs. BUCYVP16 Conditioning Prior to Autologous Hematopoeitic Stem Cell Transplantation with Hodgkin’s Lymphoma. Manuscript in Process

Yvonne Efebera, MD 6-Jun-17

7. Yvonne A. Efebera, MD, MPH*; Sara Singer, MD*; Qiuhong Zhao, MS; Donna Abounader, MS; Patrick Elder, MS; Craig C.Hofmeister, MD, MPH; Don M. Benson, MD, Ph.D; Sam Penza, MD; Leslie Andritsos, MD; Rebecca Klisovic, MD; Sumithira Vasu, MBBS; William Blum, MD2; Samantha Jaglowski, MD, MPH2; Basem M. William, MD2; Brian Bolwell, MD; Brad Pohlman, MD; Matt Kalaycio, MD; Deepa Jagadeesh, MD, MPH; Brian Hill, MD, Ph.D; Ronald Sobecks, MD; Navneet Majhail, MD, MS; Steven M. Devine, MD; Robert Dean, MD. A Two-Center Comparison of BEAM vs. BUCYVP16 Conditioning Prior to Autologous Hematopoeitic Stem Cell Transplantation with Non-Hodgkin’s Lymphoma. Manuscript in Process

8. Ranganathan P, Ngankeu A, Zitzer NC, Leoncini P, Yu X, Casadei L, Challagundla K, Reichenbach DK, Garman S, Ruppert AS, Volinia S, Hofstetter J, Efebera YA, Devine SM, Blazar BR, Fabbri M, Garzon R. Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. J Immunol. 2017 Feb 3. jimmunol.1601778. [Epub ahead of print] PMID: 28159900

9. Yi-Bin Chen, Miguel-Angel Perales, Shuli Li, Maria Kempner, Carol Reynolds, Jami Brown, Yvonne A. Efebera, Steven M. Devine, Areej El-Jawahri, Steven L. McAfee, Thomas R. Spitzer, Robert J. Soiffer, Jerome Ritz and Corey Cutler. Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD). Accepted Blood 2017

10. Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clin Pharmacol Ther. 2017 Feb 4. Epub ahead of print] PMID:28160288.

11. Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798. PMID:28194439

12. Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, R Bachier C, Martin P, Duramad

O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD. Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant. 2017 Jan 16 [Epub ahead of print]. PMID: 28104514

13. Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers ME, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JL, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J. Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016 Sep 13. pii: blood-2015-09-669846. [Epub ahead of print] PMID: 27625357

14. Yu Kyoung Cho, Douglas Sborov, Misty Lamprecht, Junan Li, Jiang Wang, Erinn Hade, Yue Gao,

Karen Tackett, Nita Williams, Don Benson, Yvonne Efebera, Ashley Rosko, Steve Devine, Ming Poi, Craig Hofmeister, and Mitch Phelps; Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clinical Pharmacology & Therapeutics 1/2017 [Paper #2016-0457R1]

15. Dorota Rowczenio, Maria Stensland, Gustavo Antonio de Souza, Erik H. Strøm, Janet A Gilbertson,

Nigel Rendell, Graham Taylor, Shane Minogue, Yvonne A. Efebera, Helen J Lachmann, Ashutosh D Wechalekar, Philip N Hawkins, Ketil Riddervold, Kristian Selvig, Inger Karin Lægreid, Julian D. Gillmore, and Tale Norbye Wien. Renal amyloidosis associated with five novel variants in the fibrinogen A-alpha chain protein. in Kidney International Reports accepted for publication), 2016

Yvonne Efebera, MD 6-Jun-17

16. S Vasu, H Wu, A Satoskar, M Puto, J Roddy, W Blum, R Klisovic, L Andritsos, C Hofmeister, D M Benson, Y Efebera, S Jaglowski, S Penza, D Cohen, S Devine and S Cataland1. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy; Bone Marrow Transplantation 11 April 2016 (Epub ahead of print] PMID 270646689

17. Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R,

Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2016 April; 22(4): 658-668 pii: S1083-8791(15)01910-2 [Epub ahead of print] PMID:26743340

18. Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget. 2015 Sep 25; 6(31): 31134-31150 [Epub ahead of print]. PMC4741593

19. Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R,

Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2015 Dec 29. pii: S1083-8791(15)01910-2 [Epub ahead of print] PMID:26743340

20. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Jin L, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia Sanz R, Hillengass J, Holstein S, Johnsen H, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Rivas E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre C, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Sep 28. pii: S1083-8791(15)00641-2. [Epub ahead of print]. PMC4757494

21. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wölfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE. International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium Biol Blood Marrow Transplant. 2015 Sep 16. pii: S1083-8791(15)00602-3.[Epub ahead of print] PMID26386318. PMCID 4706482

22. Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Cancer Res, May 2015 [Epub ahead of print}, PMID 25999435. PMCID 4573800

23. Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM. Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT). Biol Blood and Marrow Transplant, Aug 2015 {Epub, ahead of print}. PMID 26256940. PMCID 4706501

Yvonne Efebera, MD 6-Jun-17

24. Roddy JVF, Haverkos BM, McBride A, Leininger KM, Andritsos LA, Devine SM, Efebera YA. Tocilizumab for steroid refractory Acute Graft versus Host Disease. Leuk Lymphoma. 2015 Jul 3:1-5. [Epub ahead of print] PMID: 26140610

25. Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K, Efebera Y, Devine S,

Hofmeister CC. lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br J Haematol. 2015 Jun 8. [Epub ahead of print]. PMID 26058589

26. Rosko A, Hofmeister C, Benson D, Efebera Y, Huang Y, Gillahan J, Byrd JC, Burd CE.

Autologous hematopoietic stem cell transplant induces molecular aging of T-cells in multiple myeloma. Bone Marrow Transplant. 2015 Jun 29. doi: 10.1038/bmt.2015.143. [Epub ahead of print] No abstract available. PMID:26121107

27. Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Cancer Res, May 2015 [Epub ahead of print}, PMID 25999435. PMCID P

28. Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA. Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2015 Apr;56(4):1058-65. doi: 10.3109/10428194.2014.956314. Epub 2014 Nov 20 PMC4417073

29. Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T,

Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematology 2015 Apr; 169(1):36-43. PMID 25572917, PMCID P

30. Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R,

Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2015 April; 22(4): 658-668 pii: S1083-8791(15)01910-2 [Epub ahead of print] PMID:26743340

31. Sborov DW, Nuovo GJ, Stiff A, Mace TA, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE,

Pichiorri F, Grever MR, Hofmeister CC. A Phase 1 Trial of Single Agent Reolysin in Patients with Relpased Multiple Myeloma. Clin Cancer Res. 2014 Oct 7. PMID:25294913. PMCID: 4253985

32. John E. Levine, William J. Hogan, MD, Andrew C. Harris, MD, Mark R. Litzow,MD, Yvonne A.

Efebera, MD, Steven M. Devine, MD, Ran Reshef, MD, James L.M. Ferrara, MD, DSc. Improved accuracy of acute graft-versus-host disease staging among multiple centers. Best Practice & Research Clinical Haematology, Oct 2014, 283-287, PMID 25455279. PMCID P

33. Efebera,YA. It is time to move forward with Waldenstrom. Invited Commentary. Blood. 2014. Jun

26;123(26):4007-8. PMID 24970926. PMCID P

34. Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia 2014 Mar 12. PMID 24813918. PMCID:4155011

35. Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera

YA, Benson DM Jr, Devine SM, Andritsos LA. The hematopoietic stem cell transplant comorbidity

Yvonne Efebera, MD 6-Jun-17

index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. Bone Marrow Transplant. 2014 Oct; 49(10):1323-9. doi: 10.1038/bmt.2014.155. Epub 2014 Jul 28. PMID: 25068419, PMCID: PMC4192086

36. Efebera YA, Sturm A, Baack EC, Hofmeister CC, Satoskar A, Nadasdy T, Nadasdy G, Benson DM,

Gillmore JD, Hawkins PN, Rowczenio D. Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred. Amyloid. 2014 Jun;21(2):110-2. doi: 10.3109/13506129.2014.891502. Epub 2014 Mar 6. PMCID:PMC4061150

37. Roddy JVF, Haverkos BM, McBride A, Leininger KM, Andritsos LA, Devine SM, Efebera YA.

Tocilizumab for steroid refractory Acute Graft versus Host Disease. Leuk Lymphoma. 57(1): 81-85 38. Chu B, Sell M, Tucker J, Shana' ah A, Hofmeister CC, Pichiorri F, Benson, DM Jr, Efebera YA. Long

Term Therapy with Lenalidomide in a patient with POEMS Syndrome. EUR J Case Rep Intern Med 1; pii: 2014_000093 2014.

39. Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera

YA, Sexton J, Lin TS, Grever M, Byrd JC. A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol. 2014 Feb;73(2):249-57. doi: 10.1007/s00280-013-2347-y. Epub 2013 Nov 16. PMCID: PMC3946636

40. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello

D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013 Dec;62(12):1841-9. PMID:24162108 [PubMed - in process]

41. Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA,

Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F. Characterization of multiple myeloma vesicles by label-free relative quantitation. Proteomics, 2013, Oct;13(20):3013-29 PMCID: PMC3835174

42. Ferreira L, Efebera Y, Allen CM. CLINICAL PATHOLOGIC CONFERENCE CASE 2: A DIFFUSE

SWELLING OF THE NECK : a diffuse swelling of the neck. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 May;115(5):e36-40. PMID: 23738343

43. Dunavin NC, Wei L, Elder P, Phillips G, Benson DM Jr., Hofmeister CC, Penza S, Greenfield C,

Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. “Early versus delayed autologous stem cell transplantation in patients receiving novel therapies for Multiple Myeloma”. Leukemia Lymphoma. 2013 Aug; 54(8): 1658-64 Epub 2012 Dec 31. PMCID: PMC3769940

44. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R,

Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012 Nov 22;120(22):4324-33. doi:10.1182/blood-2012-06-438028. Epub 2012 Oct 1. PMCID: PMC3507143

45. Crawford MS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr. “Serum free

light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents”. Hematol Oncol. 2012. Sept; 30(3): 156-62. doi: 10.1002/hon.1019. [Epub ahead of print] PMCID: PMC 3557798

46. Benson DM, Bakan CE, Shuhong Z, Collins SM, Liang J, Shivani S, Hofmeister CC, Efebera Y,

Pascale A, Francois R, Blery M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. "IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect". Blood. 2011 Dec 8;118(24):6387-91 PMCID: PMC3490103

Yvonne Efebera, MD 6-Jun-17

47. Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A, Nadasdy T. “Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing”. AM J Surg pathol. 2011 Nov;35(11):1685-90. PMCID: PMC4061151

48. Mori S, Crawford MS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr.

Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. Hematol Oncol. 2012. Sept; 30(3): 156-62.PMID:22028144, PMCID:PMC 3557798

49. Efebera YA. Necrobiotic Xanthogranuloma. “Commentary on Clin Adv Hematol Oncol”. 2011

Sept;9(9):700-701. PMCID: PMC3495057 50. Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner

P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM “Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic hematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning”. Hematol Oncol. 2011 Dec; 29(4):202-10. doi: 10.1002/hon.985 Epub 2011 Feb 28.PMCID: PMC3557914

51. Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, MD; Hosing C, Rondon G,

Champlin R, Giralt S. “The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes” . Internet J. Hematology ISSN 1540-2649. 2010. Volume 7 Number 1. doi: 10.5580/17d5. PMCID: PMC385293

52. Efebera YA, Blanchard E, Allam C, Han A, Lee S, Munshi N. “Complete Response to Thalidomide

and Dexamethasone in a patient with Necrobiotic Xanthogranuloma Associated with Monoclonal Gammopath”. A Case Report and Review of the Literature. Clinical Lymphoma Myeloma and Leukemia. 2011 Jun; 11(3):298-302. Epub 2011 Apr 20 PMCID: PMC3390934

53. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu

J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. “The PD-1 / PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody”. Blood. 2010 Sep 30; 116(13):2286-94. PMCID: PMC3490105.

54. Efebera YA, de Lima M. “Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia: Who Should BeTransplanted in First Complete Remission?” ASCO Educational Book Manuscript 2010 Educational Book - Category: Leukemia, Myelodysplasia, and Transplantation

55. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M,

Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. “Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma”. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1122-9. Epub 2010 Feb 21. PMCID: PMC3414196

56. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C,

Popat U, Efebera Y, Champlin RE, de Lima M. “Moderate Renal Function Impairment does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation”. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1094-9. PMCID: PMC2434387

57. Ahmadi T, Flies A, Efebera Y, Sherr D. “CD40 Ligand-activated, Antigen-specific B cells are

Comparable to Mature Dendritic cells in Presenting Protein Antigens and MHC Class1- and Class11-Binding peptides”. Immunology, 2008 May; 124(1):129-140. PMCID: PMC2434387

Yvonne Efebera, MD 6-Jun-17

58. Szymanska G, Stromer H, Silverman M, Belu-John Y, Morgan JP. “Altered Phosphorylation of Sarcoplasmic Reticulum Contributes to the Diminished Contractile Response to Isoproteronol in Hypertrophied Rat Hearts”. European Journal of Physiology. 1999. 439: 1-10.PMID 10650994

ABSTRACTS 1. Singer S, Efebera YE; Zhao Q, Abounader D, Elder P,.Hofmeister CC, Benson DM, Penza S,

Andritsos L, Klisovic,R, Vasu S, Blum W, Jaglowski S, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Majhail N, Devine SM, Dean R. A TWO-CENTER RETROSEPECTIVE COMPARISON OF BEAM VS. BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN’S LYMPHOMA; European Society of Haematology 2016. Poster

2. Paul G. Richardson, Craig C. Hofmeister, Noopur S. Raje, David S. Siegel, Sagar Lonial, Jacob

Laubach, Yvonne A. Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Mohamed H. Zaki, Jennifer Herring, Yan Li, Sheetal Shah, Min S. Chen, Kenneth C. Anderson. POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH PROTEASOME INHIBITOR–EXPOSED AND LENALIDOMIDE-REFRACTORY MYELOMA: RESULTS OF A MULTICENTER, DOSE-ESCLATION, PHASE 1 TRIAL (MM-005). European Society of Haematology 2016. Poster.

3. Hassan Issa, Amy S. Ruppert, Patrick Elder, Craig C. Hofmeister, Don M Benson, Sam Penza, Leslie

A. Andritsos, Rebecca B. Klisovic, Sumithira Vasu, William Blum, Samantha M. Jaglowski, Steven M. Devine, Yvonne A Efebera. Antithymocyte Globulin (ATG) 4.5 vs. 6.0 mg/kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). BMT Tandem Annual Meeting. Biology of Blood and Marrow Transplantation. Feb 2016; Volume 22, Issue 3, Supplement, Pages S316–S317. Poster Presentation

4. Marcello Rotta, MD, Lai Wei, PhD, Rhonda Kitzler, MS, Hillary Bradbury, MS, ASCP, Anissa

Bingman, MS, Sumithira Vasu, MBBS, Samantha Jaglowski, MD, MPH, William Blum, MD, Rebecca Klisovic, MD, Sam Penza, MD, Leslie A Andritsos, MD, Yvonne A. Efebera, MD, MPH, Gerard Lozanski, MD and Steven M. Devine, MD. Significant impact of mobilization strategy on the cellular composition of donor allografts; Biology of Blood and Marrow Transplantation. Feb 2016;Volume 22, Issue 3, Supplement, Pages S351–S352. Poster Presentation

5. Parvathi Ranganathan, Ngankeu, Apollinaire, Yvonne Efebera, Keli Hippen, Bruce Blazar, Steven

Devine, Ramiro Garzon. miR-155 affects T cell migration in acute Graft Versus Host Disease (aGVHD). EBMT 2015, Abstract 090. Oral presentation.

6. Yvonne A. Efebera, Susan Geyer, Leslie Andritsos, Sumithira Vasu, Samantha Jaglowski, Anissa

Bingman, William Blum, Rebecca Klisovic, Craig C. Hofmeister, Don M. Benson, Sam Penza, Patrick Elder, Katie Cortright, Rhonda Kitzler, Kevin Coombes, Lynn O’Donnell, Beth Daneault, Hillary Bradbury, Jianying Zhang, Xilin Chen, Sabrina Garman, Parvathi Ranganathan, Xueyan Yu, Jessica Hofstetter, BS; Jianhua Yu, Ph.D; Ramiro Garzon, MD; Scott R. Scrape,MD; Steven M. Devine,; Gerard Lozanski. Impact of Atorvastatin on Immune Reconstitution and cytokines of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). EBMT 2015, Abstract 555. Poster presentation.

7. Yvonne A. Efebera, Susan Geyer, Anissa Bingman, Patrick Elder, Rhonda Kitzler, Kevin Coombes,

Carrie Hennelly, Katie Cortright, Leslie Andritsos, Samantha Jaglowski, Sumithira Vasu, William Blum, Rebecca Klisovic, Sam Penza, Craig Hofmeister, Don M. Benson, Garard Lozanski, Steven M Devine. Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT). EBMT 2015, Abstract 554. Poster presentation.

Yvonne Efebera, MD 6-Jun-17

8. Yvonne A. Efebera; Susan Geyer, Anissa Bingman, Rhonda Kitzler, Patrick Elder, Leslie Andritsos, Samantha Jaglowski , Sumithira Vasu, William Blum, Rebecca Klisovic, Sam Penza, Kevin Coombes , Craig C.Hofmeister, Don M. Benson, Steven M. Devine, Gerard Lozanski. Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). Blood (ASH Annual Meeting Abstracts), Dec 2014; abstract 124:1166. Poster Presentation

9. Yvonne A. Efebera; Susan Geyer, Anissa Bingman, Patrick Elder, Rhonda Kitzler, Kevin Coombes, Carrie Hennell, Katie Cortright, Leslie Andritsos, Samantha Jaglowski , Sumithira Vasu, William Blum, Rebecca Klisovic, Sam Penza, Sumithira Vasu, Craig C Hofmeister, Don M. Benson, Gerard Lozanski, Steven M. Devine. Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT). Blood (ASH Annual Meeting Abstracts), Dec 2014; abstract 124: 3929. Poster Presentation

10. Douglas W. Sborov, Misty Lamprecht, Don Benson, Karen Tackett, Yvonne A Efebera, Rosko E

Ashley, Steven M. Devine, Ming Poi, Mitch A. Phelps, Craig C Hofmeister. 2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial. Blood (ASH Annual Meeting Abstracts), Dec 2014; abstract 124: 3960. Poster Presentation

11. Sumithira Vasu, Anissa Bingman, Susan Geyer, Patrick Elder, Rhonda Kitzler, Hillary Bradbury, Lynn

Odonnell, William Blum, Samantha M. Jaglowski, Leslie A. Andritsos, Rebecca B. Klisovic, Sam Penza, Yvonne A Efebera, Craig C. Hofmeister, Don M. Benson, Natarajan Muthusamy, Gerard Lozanski, Steven M. Devine. Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), Dec 2014; abstract 124: 2494 Poster Presentation

12. Ashley E. Rosko, Craig C Hofmeister, Don Benson, Yvonne A Efebera, Ying Huang, Christin Burd.

T-Cell p16INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), Dec 2014; abstract 124: 2023 Poster Presentation.

13. Hector Cordero-Nieves, Douglas W. Sborov, Alessandro Canella, Zhongfa Liu, Jessica Consiglio,

Wenjun Ni, Emily Smith, Lara Rizzotto, Yvonne A Efebera, Don M. Benson, Luciano Cascione, Mo Xiaokui, John C. Byrd, Michael R. Grever, Craig C Hofmeister, Flavia Pichiorri. HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide. Blood (ASH Annual Meeting Abstracts), Dec 2014; abstract 124: 3377 Poster Presentation.

14. Yvonne A Efebera, Parvathi Ranganathan, Xueyan Yu, Jessica Hofstetter, Sabrina L Garman,

Cecilia Fernandez-Cymering, Steven M. Devine, Muller Fabbri, Ramiro Garzon. Serum Mir-29a Is Up-Regulated In Acute Graft Versus Host Disease (aGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) and Activates Dendritic Cells (DCs). EHA 2014.

15. Paul G. Richardson, Craig C. Hofmeister, Noopur S. Raje, David S. Siegel, Sagar Lonial, Jacob

Laubach, Yvonne A. Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Mohamed H. Zaki, Ye Hua, Yan Li, Sheetal Shah, Jianming Wang, Kenneth C. Anderson. Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) in Lenalidomide-Refractory and Proteasome Inhibitor-Exposed Myeloma: The Phase 1 MM-005 Trial. (ASCO Meeting Abstracts) May 2014; 32: 8589.

16. Paul G. Richardson, Craig C. Hofmeister, David S. Siegel, Sagar Lonial, Jacob Laubach, Yvonne A.

Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Noopur S. Raje, Mohamed H. Zaki, Ye Hua, Yan Li, Sheetal Shah, Jianming Wang, and Kenneth C. Anderson. MM-005: phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX; PVD) in

Yvonne Efebera, MD 6-Jun-17

lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma. ASCO 2014 abstract # 8589. Poster

17. Bradley M. Haverkos, Ali McBride, Kathryn M Leininger, Leslie a. Andritsos, Steven M Devine,

Yvonne A Efebera. Tocilizumab In The Treatment Of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. Blood (ASH Annual Abstracts) Nov 2013; 122: Abstract #2067

18. Julianna V.F. Roddy, Bradley M. Haverkos, Ali McBride, Kathryn M. Leininger, Leslie A. Andritsos,

Steven M. Devine, Yvonne A. Efebera. Tocilizumab in the Treatment of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. Blood (ASH Annual Meeting Abstracts) Nov 2013; 122(21): abstract #2067. Poster Presentation

19. Yvonne Efebera, Parvathi Ranganathan, Xueyan Yu, Jessica Hofstetter, Sabrina Garman, Laura

Gibson, William Petros, Michael Criag, Cecilia Fernandez-Cymering, Mehdi Hamadani, Guido Marcucci, Steven Devine, Muller Fabbri, Ramiro Garzon. Serum miR-29a is up-regulated in acute graft versus host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo HSCT) and activates dendritic cells (DCs). Blood (ASH Annual Meeting Abstracts), Oct 2013; 112(21):abstract #4471. Poster Presentation

20. Douglas W. Sborov, Gerard Nuovo, Nita Williams, Andrew Stiff, Thomas Mace, Gregory Lesinski Don

M. Benson, Yvonne A. Efebera, Ashley E. Rosko, Flavia Pichorri, Craig C. Hofmeister. A Phase 1Trial of Reolysin Alone in Patients with Refractory or Relapsed Multiple Myeloma Blood (ASH Annual Meeting Abstracts) Nov 2013; abstract #3208. Poster Presentation

21. Paul G. Richardson, Craig C. Hofmeister, David Siegel, Sagar Lonial, Jacob P. Laubach, Yvonne A.

Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Noopur Raje, Mohamed H. Zaki, Ye Hua, MD, Yan Li, Sheetal Shah, Jianming Wang, Kenneth C. Anderson. MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM) (ASH Annual Abstracts) Blood. 2013; 121:5055-5063 abstract #1968 [Epub ahead of print Mar 2013] doi:10.1182/blood-2012-11-469452

22. Don M. Benson , Adam D Cohen, Craig C Hofmeister, Munshi C Nikhil, Sundar Jagannath, Yvonne

A Efebera, Gary Spitzer, Robert Zerbib, Pascale Andre, Shawna Oxier, Michael A. Caligiuri. A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. Blood (ASH Annual Abstracts) 2012 Nov;120(21): abstract #4058

23. Flavia Pichiorri, Alberto Rocci, Craig C Hofmeister, Susan Geyer, Tiffany Talabere, Massimiliano

Gambella, Luciano Cascione, Andrew Stiff, Don M. Benson Jr., Yvonne A Efebera, Vijaya Dirisala, Emily M Smith, Paola Omedè, Pellegrino Musto, Davide Rossi, Silvia Gentili, Giuseppina Uccello, Roberto Ria, Giulia Benevolo, Sara Bringhen, Vincenzo Callea, Brendan M Weiss, Alfredo Ferro, Valeria Magarotto, Hansjuerg Alder, John C. Byrd, Mario Boccadoro, Guido Marcucci, Antonio Palumbo. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), Dec 2013; abstract #1853. Poster Presentation

24. Paul Gerard Guy Richardson, Craig C. Hofmeister, David Samuel DiCapua Siegel, Sagar Lonial, Jacob

Laubach, Yvonne Adeduni Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn Rosenblatt, Noopur S. Raje, Mohamed H. Zaki, Ye Hua, Sheetal Shah, Jianming Wang, and Kenneth Carl Anderson. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). (ASCO Meeting Abstracts) May 2013; 31: abstract #8584

25. Benjamin Chu, Megan Sell, Jill Tucker, Arwa Shana' ah, Craig C. Hofmeister, Flavia Pichiorri, Don M.

Benson, Yvonne A. Efebera. Long Term Lenalidomide and Dexamethasone Therapy Without Autologous Stem Cell Transplant (ASCT) in a patient with POEMS Syndrome. International Myeloma Workshop, Kyoto, Japan; Abstract # 75. Poster Presentation

Yvonne Efebera, MD 6-Jun-17

26. Yvonne A. Efebera, Parvathi Ranganathan, Xueyan Yu, Jessica Hofstetter, Sabrina Garman, Laura Gibson, William Petros, Michael Criag, Cecilia Fernandez-Cymering, Stefano Volinia, Mehdi Hamadani, Guido Marcucci, Steven Devine and Ramiro Garzon. Serum microRNAs signatures in acute graft versus host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo HSCT). EHA 2013

27. Paul G. Richardson, Craig C. Hofmeister, David S. Siegel, Sagar Lonial, Jacob Laubach, Yvonne

Efebera, David H. Vesole, Ajay Nooka, Mohamed H. Zaki, Ye Hua, Sheetal Shah, Jianming Wang, and Kenneth C. Anderson. MM-005: A phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone in relapsed and/or refractory multiple myeloma (RRMM). EHA 2013

28. Cohen JB, McBride A, Geyer S, Bingman A, Elder P, Blum W, KlisoviC R, Penza S, Andritsos LA,

Benson DM, Efebera Y, Hofineister CC, Garzon R, MarcuccI G, Devine SM. "Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics. BMT Tandem Annual Meeting. " Biology of Blood and Marrow Transplantation. Feb 2013; 19(2): S320-S321. Poster Presentation

29. Yvonne A. Efebera, Susan Geyer, Anissa Bingman, Rhonda Kitzler, Patrick Elder, Carrie Hennelly,

Leslie Andritsos, Samantha Jaglowski, William Blum, Rebecca Klisovic, Sam Penza, Sumithira Vasu, Craig C.Hofmeister, Don M. Benson, Steven M. Devine, Gerard Lozanski. Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic HematopoieticStem Cell Transplantation (AHSCT). American Society for Blood and Marrow Transplantation (ASBMT) Annual Meeting. Biology of Blood and Marrow Transplantation. Feb 2013; 19(2): S202 abstract #178. Poster Presentation

30. Akshata Pandit, Lai Wei, Patrick Elder, William Falk, Megan Sell, MS, Craig C. Hofmeister, Don M.

Benson, Sam Penza, Leslie Andritsos, Rebecca Klisovic, Sumithira Vasu, William Blum, Steven M. Devine, Samantha Jaglowski, Yvonne A. Efebera. Autologous Hematopoietic Stem Cell Transplant (HSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis). American Society Of Blood and Marrow Transplantation (ASBMT) Annual Meeting. Biology of Blood and Marrow Transplantation Feb 2013; 19(2): S186 abstract #145. Poster Presentation

31. Galena Salem, Amy S. Ruppert, Patrick Elder, Craig C.Hofmeister, Don M. Benson, Sam Penza,

Leslie Andritsos, Rebecca Klisovic, Sumithira Vasu, William Blum, Steven M Devine, Samantha Jaglowski, Yvonne A. Efebera. Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT). American Society for Blood and Marrow Transplantation (ASBMT) Annual Meeting Feb 2013; 19(2): S304-305 abstract #391. Poster Presentation

32. Andrew Stiff, Alberto Rocci, Craig C. Hofmeister, Paola Omedè, Susan Geyer, Sara Bringhen,

Luciano Cascione, Anissa Bingman, Manuela Gambella, Federica Cavallo, Luciana De Luca, Jingwen Guan, Alessandra Larocca, Jacqueline Corry, Francesca Gay, Yvonne A Efebera, Uccello G, Don M. Benson, Jr., Tiffany Talabere, Kevin Murnan, Magarotto Valeria, Mario Boccadoro, Carlo M. Croce, Antonio Palumbo, Flavia Pichiorri. miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120(21): abstract #2921. Poster Presentation.

33. Samantha M. Jaglowski, Sumithira Vasu, Susan Geyer, Anissa Bingman, Patrick Elder, Jianhua Yu,

William Blum, Rebecca B Klisovic, Sam Penza, Yvonne A Efebera, Craig C. Hofmeister, Don M. Benson, Jr., Natarajan Muthusamy, Steven M. Devine, Leslie A Andritsos, Gerard Lozanski. Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: abstract #1949. Poster Presentation

Yvonne Efebera, MD 6-Jun-17

34. McDonagh H, Falk W, Bingman A, Geyer S, Benson D, Efebera YA, Hofmeister C,. "Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma." Blood. (ASH Annual Meeting Abstracts) Nov 2012; 120 (21): abstract #4978. Poster Presentation

35. Sumithira Vasu, Samantha M. Jaglowski, Susan Geyer, Anissa Bingman, Patrick Elder, Jianhua Yu,

Leslie A Andritsos, William Blum, Rebecca B Klisovic, Sam Penza, Yvonne A Efebera, Craig C. Hofmeister, Don M. Benson, Jr., Natarajan Muthusamy, Steven M. Devine, Gerard Lozanski. Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD). Blood (ASH Annual Meeting Abstracts), Nov 2012; 120(21) abstract #4192. Poster Presentation.

36. Benson Jr. DM, Cohen AD, Munsh NCi, Jagannath S, Spitzer G, Hofmeister CC, Zerbib R, Andre P,

Efebera YA, Oxier S, Caligiuri MA. A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. Blood (ASH Annual Meeting Abstracts) Nov 2012; 120(21): abstract #4058

37. Mehdi Hamadani, Michael Craig, Scot Remick, Laura Gibson, William Petros, Jame Abraham, Aaron

Cumpston, Pamela Bunner, Soumit Basu, William Tse, Carrie Hennelly, Sumi Vasu, Rebecca Klisovic, William Blum, Samantha Jaglowski, Don Benson, Leslie Andritsos, Sam Penza, Craig Hofmeister, Susan Geyer, Steven M. Devine, Yvonne Efebera. Immunomodulation of Both Donors and Recipients with Atorvastatin as a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). Blood (ASH Annual Meeting Abstracts) Nov. 2012; 120(21): abstract #1939.

38. Hofmeister CC, Bowers MA, Efebera YA, Humphries K, Benson Jr. DM, Greenfield CN, Sell M,

Devine SM. Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) Nov 2012; 120(21): abstract #3114.

39. Hofmeister CC, Bowers MA, Bingman A, Lozanski G, Baiocchi RA, Falk W, Benson DM, Jr., Efebera

YA, Humphries K, Sell M, Greenfield CN, Lustberg ME, Vaughn JL, Earl CT, Geyer S, Devine SM. Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma. Blood. (ASH Annual Meeting Abstracts) Nov 2012; 120(21): 4460

40. Jaglowski SM, Hofmeister C, Elder P, Penza S, Efebera YA, Benson Jr DM, Devine SM, Andritsos

LA. The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) Nov 2012; 120: abstract #4286.

41. Yvonne A. Efebera, Dorota Rowczenio, Anjali Satoskar, Don M. Benson M.D, Tibor Nadasdy, Philip

N. Hawkins.. Renal amyloidosis associated with a novel fibrinogen A alpha chain mutation. XIIIth International Symposium on Amyloidosis. The Netherlands May 2012.

42. Dorota Rowczenio, Glenys A Tennent, Helen J Lachmann, Alison Bybee, Janet Gilbertson, Yvonne

Efebera, Anjali Satoskar, Tibor Nadasdy, Ahmet Dogan, Philip N Hawkins and Julian D Gillmore. Hereditary gelsolin amyloidosis: a novel variant N211K, and a review of the clinical, histological and SAP scintigraphic characteristics. XIIIth International Symposium on Amyloidosis, The Netherlands May 2012.

43. Galena Salem, Neil Dunavin, Lai Wei, Pat Elder, Sam Penza, Kristie Blum, Pierlugi Porcu, Robert

Baiocchi, Jeffrey Jones, Joseph Flynn, Leslie Andritsos, Steven M Devine, Beth Christian, Yvonne Efebera. Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity. (EBMT 2012 Congress Oral presentation), Bone Marrow Transplantation April 2012; 47(S84): abstract #0365.

Yvonne Efebera, MD 6-Jun-17

44. Salem G, Ruppert AS, Efebera Y, Elder P, Bingman A, Penza S, Andritsos L A, Devine SM. Busulfan, cyclophosphamie, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)ASBMT annual meeting. Biology of Blood and Marrow Transplantation Feb 2012; 18(2): S246 abstract #115.

45. Simrit Parmar, Gabriela Rondon, Peter F Thall, Roland Bassett, Marcos De Lima, Chitra M Hosing,

Paolo Anderlini, Partow Kebriaei, Issa Khouri, Prasanth Ganesan, Yvonne A Efebera, Richard Champlin, and Sergio A Giralt. Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens. Blood (ASH Annual Meeting Abstracts) Nov 2011; 118(21): 848 abstract #1944.

46. Nikhil C. Munshi, Saem Lee, Suman Kambhampati, Michal Rose, Abid Mohiuddin, Yvonne Efebera,

Andrew Han, Antoun Houranieh, Abraham Zimelman, Mary T. Brophy, Rao Prabhala, Terrence Grady, Paulette Mehta, Teresa G Hayes, Sarvari Venkata Yellapragada, Caroline Behler, Catherine Klein, David Roodman, and Alan K. Lichtenstein. Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities. Blood (ASH Annual Meeting Abstracts) Nov 2011; 118(21)1695-96 abstract #3964.

47. Neil Dunavin, Joyce Habib, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M Benson, Jr.,

Craig C. Hofmeister, John C. Byrd, Steven M. Devine, Yvonne Efebera. Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) Nov 2010; 116(21): 1466-67 abstract #3564.

48. Joyce Habib, Neil Dunavin, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M Benson, Jr.,

Craig C. Hofmeister, John C. Byrd, Steven M. Devine, Yvonne Efebera. Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study. Blood. (ASH Annual Meeting Abstracts) Nov 2010; 116(21): 575-76 abstract #1343.

49. Nikhil C. Munshi, Saem Lee, Suman Kambhampati, Abid Mohiuddin, Michal Rose, Caroline Behler,

Andrew Han, Yvonne Efebera, Antoun Houranieh, Mary T. Brophy, Abraham Zimelman, Rao H Prabhala, Hussain I. Saba, Catherine Klein, Paulette Mehta, Teresa Hayes, David Roodman, Alan K. Lichtenstein. Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities. Blood. (ASH Annual Meeting Abstracts) Nov 2010; 116(21): 1262-63 abstract #3061

50. Craig C. Hofmeister, Gisele Rieser, Mindy A Bowers, Lisa C Merritt, Carli N Greenfield, Yvonne A

Efebera, Don M Benson, Jr., Steven M Devine, Janet S de Moor. Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors. Blood (ASH Annual Meeting Abstracts) Nov 2010; 116(21):1557 abstract #3807.

51. Don M Benson, Jr, Courtney E Bakan, Swaminathan Padmanaban, Rafat Abonour, Attaya

Suvannasankha, Sundar Jagannath, Ajai Chari, David Clever, Chidimma Kalu, Shauna Collins, Yousef Alghothani, Craig C. Hofmeister, Yvonne Efebera, Stephane Blanchet, Michael A. Caligiuri, and Sherif Farag. IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. Blood (ASH Annual Meeting Abstracts) Nov 2010; 116(21): 821 abstract #1966.

52. D. M. Benson, S. Padmanabhan, C. C. Hofmeister, C. E. Bakan, R. Abonour, A. Suvannasankha, Y.

A. Efebera, P. J. Squiban, M. A. Caligiuri, S. Farag. A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma. J Clin Oncol 2010; 28(7s) abstract #8139

Yvonne Efebera, MD 6-Jun-17

53. Don Benson, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, Yvonne A Efebera, Megan K Smith, Carli N Greenfield, Pascale Andre, Patrick Squiban, Francois Romagne, Michael A. Caligiuri, and Steven M Devine. Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) Nov 2009; 116: abstract #4641

54. Rao H Prabhala, Yvonne A Efebera, Saem Lee, Andrew J Han, Dheeraj Pelluru, Puru Nanjappa,

Samir Amin, Christine Pai, Irene Ghobrial, Robert L Schlossman, Jacob Laubach, Mariateresa Fulciniti, Paul Richardson, Kenneth C. Anderson, Nikhil C. Munshi. Lack of Response to Vaccination in MGUS and Stable Myeloma. Blood (ASH Annual Meeting Abstracts) Nov 2009; 114(22): 734-35 abstract #1852

55. Craig C Hofmeister, M.D, Don Benson, MD, PhD, Yvonne A Efebera, M.D, Sherif Farag, MBBS,

PhD and Michael R. Grever. Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) Nov 2009; 114(22)1126: abstract #2884.

56. Efebera Y, Saliba RM, Thandi RS, Popat U, De Lima M, Alousi A, Hosing C, Ledford M, Champlin R,

Giralt S. Impact of Pre-stem Cell Transplant Ferritin Levels on late Transplant Complications. A Landmark Analysis to Determine Potential Role of Iron Chelation in Improving Outcomes. Tandem Meeting on Biology of Blood and Marrow Transplantation. (ASBMT Annual Meeting Abstracts) Biology of Blood and Marrow Transplantation. Feb 2009. 15(2)92-93: abstract #254

57. Prabhala RH, Pelluru D, Fulciniti M, NanjappA P, Prabhala NS, Mitsiaties C, Lefkimmiatis K,Tai YT,

Efebera YA, Daley JF, Anderson KC, Munshi NC. "IL-17 Promotes Tumor cell Growth and Survival, and Inhibits Immune Function in Myeloma. CLINICAL LYMPHOMA & MYELOMA. (Feb 2009). 9 S159-S159.

58. Yvonne A. Efebera, Hagop M. Kantarjian, Borje Anderson, Sherry Pierce, Leandro De Padua Silva,

Farhad Ravandi, Sergio A. Giralt, Gautam Borthakur, Richard Champlin, Marcos De Lima. Allogeneic Hematopoietic Stem Cell Transplant (HSCT) versus Conventional Chemotherapy in patients with Acute Myelogenous Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) attaining complete remission (CR1) post induction chemotherapy: A retrospective case control study. Blood (ASH annual meeting abstracts), Nov 2008; 112(11):411 abstract #1125

59. Yvonne Efebera, Elizabeth Blanchard, Charles Allam, Andrew Han, Nikhil Munshi. Complete

Response to Thalidomide and Dexamethasone in a patient with Necrobiotic Xanthogranuloma (NXG) associated with Monoclonal Gammopathy of Uncertain Significance (MGUS). Blood (ASH Annual Meeting Abstracts), Nov. 2008; 112(11): abstract #5210

60. Rao Prabhala, Dheeraj Pelluru, Mariateresa Fulciniti, Puru Nanjappa, Harsha K. Prabhala, Nithya S.

Prabhala, Constantine Mitsiades, Yu-Tzu Tai, Irene Ghobrial, Paul Richardson, Konstantinos Lefkimmiatis, John F. Daley, Yvonne A. Efebera, Kenneth C. Anderson, MD and Nikhil C. Munshi. TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. Blood (ASH Annual Meeting Abstracts) Nov 2008; 112(11): abstract #2737

61. Rao Prabhala, Dheeraj Pelluru, Paola Neri, Mariateresa Fulciniti, James Driscoll, Song Weihua,

Simona Blotta, Yu-Tzu Tai, Hiren Patel, Yvonne A. Efebera, Teru Hideshima, Dhaminder Chauhan, John F. Daley, Kenneth C. Anderson, Nikhil C. Munshi. TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1030A abstract # 3517.

62. Yvonne Efebera, Tahamtan Ahmadi, David Sherr. CD40 ligand activation alters B cell migration to

secondary lymphoid organs. (ASH Annual Meeting Abstracts), Nov 2006; 108 abstract #935.

Yvonne Efebera, MD 6-Jun-17

63. Tahamtan Ahmadi, Nathalie Weizmann, Yvonne Efebera, David Sherr. Primary antigen-specific B cells: A novel approach to cellular-based immunotherapy. Blood (ASH Annual Meeting Abstracts) Nov 2006; 108(11): 1061A-1062A abstract #3717.

64. “Heart Failure outcomes in the setting of renal dysfunction in hospitalized patients”. Advisor: Dr.

James B. Young, Head, Section of Heart Failure and Transplant Research, Cleveland Clinic Foundation.

65. Yvonne Belu-John, Byron Hoogwerf. Sulfonyl urea-induced hypoglycemia from medication

dispensing errors. Clinical Vignettes, Society of General Internal Medicine (SGIM) Annual Meeting, 2001, abstract ID #31491

66. Yvonne Belu-John, Byron Hoogwerf. Ectopic ACTH from an unusual source. American College of

Physician (ACP) Annual Meeting, 2001. 67. Yvonne Belu-John. “Video Assisted Thoracoscopic Surgery Compared to Open Laparotomy in the

Management of Thoracic Diseases”. Advisor: Dr. David Campbell, Dept. of Cardio thoracic Surgery, Pennsylvania State Univ. College of Medicine. 1997

68. Yvonne Belu-John, James P. Morgan. Quantitation of Phospholamban on the Hypertrophic and

Failing Myocardium. Summer Honors Undergraduate Research Program (SHURP), Harvard School of Medicine, and Beth Israel deaconess Medical center. MARC-MBRS Annual Conference: 1993 & 1994.

69. Yvonne Belu-John, Howard Zalkin. Synthesis and Characterization of Purine Repressor Protein.

MARC/AIM Summer Research Program- Purdue University. American Chemical Society, MARC-MBRS Annual Conference, 1992.

ORAL PRESENTATIONS National / International Meetings Efebera YA. Moderator. American Society of Hematology Oral Abstract Session. Session 731. Clinical Allogeneic and Autologous Transplantation – Results: Autologous Transplantation for Lymphoma, Myeloma and APL. December 9,2013: New Orleans, LA. Efebera YA. Moderator. Managing Myeloma: clinical dialogue in myeloma, what is the role of transplant in the era of novel agents? November 27, 2013: MedicalEd.com Efebera, YA. Media Interview: Update in Research and Graft-versus-Host-Disease. The American Society of Hematology meetings December 9, 2013. New Orleans, LA. Efebera, Y/A. Invited Speaker. 2nd Annual Summit on Lymphoid Malignancies and Multiple Myeloma: Timing and Length of Lenalidomide Maintenance in Multiple Myeloma. March 13, 2015. Whistler, Canada. Efebera, Contributor: Should stem cell transplantation remain the preferred first-line treatment for patients with multiple myeloma? HemOnc Today September 2015. http://www.healio.com/hematology-oncology/hematologic-malignancies/news/print/hemonc-today/%7B5698fdba-394a-4db1-b6cb-b6eb5a3b5470%7D/immunotherapy-triplet-regimens-drive-unprecedented-progress-in-myeloma State / Local Meetings Efebera YA, Mediator. April & September 2010. Amyloidosis Support Group: Update on Primary Amyloidosis. The Ohio State University, Columbus, OH.

Yvonne Efebera, MD 6-Jun-17

Efebera YA, Mediator. September 2010. Myeloma support group: Update on Multiple Myeloma and Treatment. Columbus, OH Efebera YA, Presenter. November 2010. Fellows Conference, “Amyloidosis Review” The Ohio State University, Division of Hematology, Columbus, OH Efebera YA, Presenter. January 2010. ASH Review. Sponsored by the Ohio State University, The Hilton Hotel, Columbus, OH. Efebera, YA. Presenter. June 2010 ASCO Review on Hematology. Sponsored by The Ohio State University, The Hilton Hotel, Columbus, OH. Efebera YA, Presenter. February 2011. Lymphoma/leukemia meeting: Multiple Myeloma update, Cincinnati, OH. Efebera YA, Presenter. March 2012. Amyloidosis Support Group. Updates in treatment of primary Amyloidosis. The Ohio State University, Columbus, OH. Efebera YA, Presenter. March 23, 2012. Grand Rounds Presentation. Updates in Multiple Myeloma, Scioto County Medical Center, Portsmouth, OH. Efebera YA, Presenter. May 29, 2012. Grand Rounds Presentation. Updates in Multiple Myeloma. MedCentral Health System, Mansfield, OH. Efebera, YA. Presenter. September 2012. Multiple Myeloma. Hicks Harris Ferguson Multiple Myeloma Symposium, Columbus, OH. Efebera YA. Presenter. April 12, 2013. Leukemia Lymphoma Society (LLS) Meeting. Multiple Myeloma, Columbus, OH. Efebera YA, Presenter, August 2, 2013. Ohio Myeloma Initiative. Multiple Myeloma, Columbus, Ohio Efebera YA, Speaker. 2013: Guest on local radio Saturday Talk Show (106.3 AM) w/Dr. William Hicks Discussion on “Multiple Myeloma; Diagnosis and Treatment “ followed by questions from listeners, Columbus, OH. Efebera YA, Presenter, August 8, 2015, Cancer Awareness Concert and Fundraiser- Giant Slayer Ministries. Efebera YA, Presenter. January 2016. ASH Review. Sponsored by the Ohio State University, Columbus, OH Regional Meetings Efebera YA, Presenter. January 2011. Fellow Board Review. The Ohio State University, Division of Hematology, Columbus, OH Efebera YA. Presenter. May 23, 2012. Nurse Practitioners Grand Grounds. What you need to know about Multiple Myeloma. The Ohio State University Medical Center Department of Nursing Education, Columbus, OH. Efebera YA. Presenter. February 5, 2013. OSU Internal Medicine Residency Forum. Blood and Marrow SCT, Columbus, OH.

Yvonne Efebera, MD 6-Jun-17

Efebera YA. Presenter. March 9, 2013. Grand Grounds Presentation on Amyloidosis, OSU Division of Rheumatology. Columbus, OH. Efebera YA, Presenter. September 29, 2014. Resident lecture, Multiple Myeloma. Radiation oncology, OSU Division of Radiation oncology. Efebera YA, presenter. October, 2014. Resident lecture, Multiple Myeloma. Internal Medicine, OSU. Efebera YA, Presenter, January 30, 2017. Resident lecture. Multiple Myeloma, Radiation Oncology OSU Division of Radiation Oncology

D. Research Support Ongoing Research support 1 K12 CA133250-01 (PI: Byrd) 9/9/2009 - 7/31/2013 NIH Translational Training Grant in Experimental Therapeutics Phase I/II study of CT-011 in combination with lenalidomide as a salvage therapy in multiple Myeloma where we sort to determine: 1) the maximum tolerated dose, toxicity, and response of CT-011 and lenalidomide in relapsed multiple myeloma, 2) if PD1 addition to lenalidomide enhances NK cell activation and direct killing of MM cells and 3) the pharmacokinetics of PD1 and relationship to enhanced NK cell activation when administered with lenalidomide. Role: Scholar CCTS: The Ohio State University and West Virginia University Collaboration Study. Applied 3/2011. Received. $50,000. Assessment of MicroRNA-155 Expression in acute Graft-versus-Host Disease (aGVHD) Role: PI NIH Loan Repayment Program 9/2012-7/2014 Evaluation of the safety and efficacy of atorvastatin for the prophylaxis of acute graft-versus-host-disease (GVHD) in patients undergoing HLA-matched related hematopoietic stem cell transplantation(HSCT). Amount: 70,000.00 Role: PI American Cancer Society 7/1/2013- 6/30/2018 A phase I/II trial of CT-011 and lenalidomide for multiple myeloma Amount: $ 790,000.000 Role: Co-PI NHLBI R21 8/1/2013- 7/30/2015 MicroRNAs as biomarkers for acute Graft-versus-host-disease Amount: $ 228,470.00 Role: Co-PI 1 R21 HL117701-01 (PI: Garzon) 09/01/2012 – 08/31/2014 0.45 calendar NHLBI $75,000 MicroRNAs as biomarkers for acute graft-versus-host disease The overall objective of this project is to expand the search for aGVHD miRNAs biomarkers, to validate candidate miRNAs and establish their prognostic significance. RSG-13-249-01 (PI: Benson) 07/01/2013 – 06/30/2017 ACS $300,000

Yvonne Efebera, MD 6-Jun-17

A Phase I/II trial of CT-011 and lenalidomide for multiple myeloma The goal of this project is to conduct a Phase I/II study of CT-011 and len in patients with relapsed/refractory MM and to assess the correlative effects of combination therapy with CT-011 and lenalidomide on T cellsb and NK cells in patients with relapsed/refractory MM Role: Co-Investigator RGI-2001-002/OSU 11052 (PI: Efebera) 10/18/2011 – 12/31/2016 REGiMMUNE Corporation $142,437 OSU 11052 - A phase 1, open-label, multicenter, dose-escalation study to evaluate the safety and tolerability of intravenous administration of RGI-2001 in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) CL-503012 (PI: Efebera) 04/26/2011 – 12/31/2016 PPD Dev $15,762 OSU 10137 - International randomized, double-blind, placebo-controlled, Phase 3 study of the efficacy and safety of KIACTA in preventing renal function decline in patients with AA amyloidosis DFCI Protocol # 12-094 (PI: Efebera) 04/08/2014 – 03/15/2019 Dana-Farber Cancer Institute $0 OSU 13168: Phase I trial of Brentuximab Vedotin for steroid refractory acute Graft-vs.-Host Disease (GVHD) A061304: (PI and Co-Chair Efebera). 06/30.2016- Phase Ib study of Ibrutinib +lenalidomide in relapse multiple myeloma patients Alliance Foundation and Pharmacyclics $1.5 million Pending and unsupported grants ROI: (CO-PI) Prognosis, Biology and Targeting of Serum miR-29a in Acute Graft-Versus-Host-Disease(GVHD). submitted 2/2016 NIH: K23 (PAR 12-052) Immunotherapy in management of graft-versus-host-disease 7/01/2013 Role: PI Pelotonia Institutional research Grant: Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease(GVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT). 5/2013 Role: PI American Society of Blood and Marrow Transplant 10/2010 Assessment of MicroRNA-155 Expression in Acute Graft-versus-Host Disease Amount: $30,000.00 Role: PI American Society of Hematology 7/2010 Assessment of MicroRNA-155 Expression in Acute Graft-versus-Host Disease Amount: $150,000.00 Role: PI CALGB (now ALLIANCE) 9/2011 Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft vs.Host Disease (GVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)

Yvonne Efebera, MD 6-Jun-17

Amount: $88,000.00 Role: PI American Society of Clinical Oncology 10/2011 Assessment of MicroRNA-155 Expression in Acute Graft-versus-Host Disease Amount: $200,000.00 Role: PI Department of Defense pre-proposal 5/2012 Immunomodulation in acute graft-versus-host-disease Role: PI Harold Amos Medical Faculty Development Program (AMFDP). 2012 Amount: $400,000.00